industry-funded-research

Astellas Brings Real-World Numbers for Its Menopause Drug to ENDO 2026. The Black Box Warning Stayed Home.

Astellas presented its first real-world numbers for Veozah at ENDO 2026, framed as a win. The 656-woman observational study had no placebo arm and the company's release did not mention the FDA black-box warning for liver injury.